Macrophage Polarization during MRONJ Development in Mice.

Journal of dental research Pub Date : 2024-08-01 Epub Date: 2024-08-05 DOI:10.1177/00220345241258990
A Soundia, N Elzakra, D Hadaya, I Gkouveris, O Bezouglaia, S Dry, T Aghaloo, S Tetradis
{"title":"Macrophage Polarization during MRONJ Development in Mice.","authors":"A Soundia, N Elzakra, D Hadaya, I Gkouveris, O Bezouglaia, S Dry, T Aghaloo, S Tetradis","doi":"10.1177/00220345241258990","DOIUrl":null,"url":null,"abstract":"<p><p>Macrophages are important regulators of bone remodeling, and M1 polarization is observed in the setting of medication-related osteonecrosis of the jaws (MRONJ). Here, we characterize the phenotype of macrophages during early stages of MRONJ development in zoledronate (ZA)-treated mice with periodontal disease and explore the role of rosiglitazone, a drug that has been reported to lower the M1/M2 macrophage ratio, in MRONJ burden. Mice received ZA, and experimental periodontal disease (EPD) was induced around their second left maxillary molar. The mice were euthanized 1, 2, or 4 wk later. Micro-computed tomography and histologic and immunohistochemical analyses were carried out. In a separate experiment, mice were treated with ZA in the absence or presence of rosiglitazone, EPD was induced for 5 wk, and the MRONJ burden was assessed. An M1 predilection was noted in ZA versus vehicle (Veh) mice at 1, 2, or 4 wk after ligature placement. M1 cells were found to be positive for MMP-13, and their presence coincided with disruption of the surrounding collagen network in ZA mice. Rosiglitazone caused a reversal in the M1/M2 polarization in Veh and ZA mice. Rosiglitazone did not cause significant radiographic changes 5 wk after EPD in Veh or ZA animals. Importantly, percentage osteonecrosis and bone exposure were decreased in the rosiglitazone-treated versus nontreated ZA sites 5 wk after EPD. Our data point to an important role of M1 macrophage polarization with an overexpression of MMP-13 in the early phases of MRONJ development and provide insight into the use of interventional approaches promoting an M2 phenotype as a preventative means to alleviate MRONJ burden.</p>","PeriodicalId":94075,"journal":{"name":"Journal of dental research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465330/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dental research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00220345241258990","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Macrophages are important regulators of bone remodeling, and M1 polarization is observed in the setting of medication-related osteonecrosis of the jaws (MRONJ). Here, we characterize the phenotype of macrophages during early stages of MRONJ development in zoledronate (ZA)-treated mice with periodontal disease and explore the role of rosiglitazone, a drug that has been reported to lower the M1/M2 macrophage ratio, in MRONJ burden. Mice received ZA, and experimental periodontal disease (EPD) was induced around their second left maxillary molar. The mice were euthanized 1, 2, or 4 wk later. Micro-computed tomography and histologic and immunohistochemical analyses were carried out. In a separate experiment, mice were treated with ZA in the absence or presence of rosiglitazone, EPD was induced for 5 wk, and the MRONJ burden was assessed. An M1 predilection was noted in ZA versus vehicle (Veh) mice at 1, 2, or 4 wk after ligature placement. M1 cells were found to be positive for MMP-13, and their presence coincided with disruption of the surrounding collagen network in ZA mice. Rosiglitazone caused a reversal in the M1/M2 polarization in Veh and ZA mice. Rosiglitazone did not cause significant radiographic changes 5 wk after EPD in Veh or ZA animals. Importantly, percentage osteonecrosis and bone exposure were decreased in the rosiglitazone-treated versus nontreated ZA sites 5 wk after EPD. Our data point to an important role of M1 macrophage polarization with an overexpression of MMP-13 in the early phases of MRONJ development and provide insight into the use of interventional approaches promoting an M2 phenotype as a preventative means to alleviate MRONJ burden.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小鼠 MRONJ 发育过程中的巨噬细胞分化
巨噬细胞是骨重塑的重要调节因子,在药物相关性颌骨坏死(MRONJ)的情况下可观察到巨噬细胞的M1极化。在这里,我们描述了唑来膦酸钠(ZA)治疗的牙周病小鼠在MRONJ发展早期阶段巨噬细胞的表型,并探讨了罗格列酮(一种据报道能降低M1/M2巨噬细胞比例的药物)在MRONJ负担中的作用。小鼠接受ZA治疗,并在左侧第二颗上颌臼齿周围诱发实验性牙周病(EPD)。小鼠在1、2或4周后被安乐死。对小鼠进行显微计算机断层扫描、组织学和免疫组化分析。在另一项实验中,小鼠在无罗格列酮或有罗格列酮的情况下接受ZA治疗,诱导EPD 5周,并评估MRONJ负担。在结扎后1、2或4周时,ZA与载体(Veh)小鼠相比,发现M1偏好。发现 M1 细胞对 MMP-13 呈阳性反应,它们的存在与ZA 小鼠周围胶原网络的破坏相吻合。罗格列酮导致Veh和ZA小鼠的M1/M2极化发生逆转。罗格列酮不会导致Veh和ZA小鼠在EPD 5周后出现明显的放射学变化。重要的是,在EPD 5周后,罗格列酮处理的ZA部位与未处理的ZA部位相比,骨坏死和骨暴露的百分比均有所下降。我们的数据表明,M1巨噬细胞极化与MMP-13的过度表达在MRONJ发展的早期阶段起着重要作用,并为使用促进M2表型的干预方法作为减轻MRONJ负担的预防手段提供了启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Oral Health Research in the WHO African Region between 2011 and 2022: A Scoping Review. Advanced Imaging in Dental Research: From Gene Mapping to AI Global Data. A Deep Learning System to Predict Epithelial Dysplasia in Oral Leukoplakia. Nuclear TOP1MT Confers Cisplatin Resistance via Pseudogene in HNSCC. Periodontitis and Diabetes Differentially Affect Inflammation in Obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1